Excerpt
Is it conceivable that for 40 years we have overlooked an insidious long-term levodopa treatment adverse effect, such as neuropathy, in idiopathic Parkinson disease (IPD)? In this issue of Neurology®, Rajabally and Martey1 take up the already controversial question, recently mooted by Toth et al.,2 of the increased prevalence of neuropathy in chronic levodopa-treated IPD and its potential but tenuous link to elevated plasma levels of homocysteine (Hcy) and methylmalonic acid (MMA) and to reduced vitamin B12 levels. Even though the role of levodopa in neuropathy is still hypothetical, the clinical relevance is evident, as sensory neuropathy may contribute to impaired balance and neuropathic pain in advanced IPD. Furthermore, vitamin B12 deficiency and increased Hcy and MMA levels can be easily determined in blood, suggesting that neuropathy as a treatment-related complication may be prevented or treated by vitamin B12 and folate supplementation.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
